Reportable Segment and Major Customers Information (Tables)

6 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Reportable Segment Information

Reportable segment and corporate information for the interim periods is as follows:

	Diagnostics			Life Science		Corporate(1)			Eliminations(2)			Total
Three Months Ended March 31, 2022
Net revenues -
Third-party	$	41,103		$	70,128	$	—		$	—		$	111,231
Inter-segment		113			32		—			(145	)		—
Operating income (loss)		1,589			40,286		(5,752	)		18			36,141
Goodwill (March 31, 2022)		94,528			19,511		—			—			114,039
Other intangible assets, net (March 31, 2022)		79,056			2		—			—			79,058
Total assets (March 31, 2022)		355,754			116,090		—			(34	)		471,810
Three Months Ended March 31, 2021
Net revenues -
Third-party	$	31,949		$	53,315	$	—		$	—		$	85,264
Inter-segment		116			91		—			(207	)		—
Operating income (loss)		2,641			36,025		(4,481	)		16			34,201
Goodwill (September 30, 2021)		94,904			19,764		—			—			114,668
Other intangible assets, net (September 30, 2021)		84,149			2		—			—			84,151
Total assets (September 30, 2021)		339,208			110,536		—			(22	)		449,722
Six Months Ended March 31, 2022
Net revenues -
Third-party	$	74,307		$	125,265	$	—		$	—		$	199,572
Inter-segment		147			87		—			(234	)		—
Operating (loss) income		(174	)		66,888		(10,323	)		33			56,424
Six Months Ended March 31, 2021
Net revenues -
Third-party	$	62,270		$	115,911	$	—		$	—		$	178,181
Inter-segment		185			109		—			(294	)		—
Operating income (loss)		1,683			75,754		(8,600	)		28			68,865

(1)  Includes selected legal costs of $508 and $789 in the three and six months ended March 31, 2022, respectively, and $1,030 and $2,257 in the three and six months ended March 31, 2021, respectively. 

(2)  Eliminations consist of inter-segment transactions.

Pre-tax Earnings Table

A reconciliation of reportable segment operating income (loss) to consolidated earnings before income taxes is as follows:

	Three Months Ended March 31,						Six Months Ended March 31,
	2022			2021			2022			2021
Operating income (loss):
Diagnostics segment	$	1,589		$	2,641		$	(174	)	$	1,683
Life Science segment		40,286			36,025			66,888			75,754
Eliminations		18			16			33			28
Total segment operating income		41,893			38,682			66,747			77,465
Corporate operating expenses		(5,752	)		(4,481	)		(10,323	)		(8,600	)
Interest income		2			6			3			15
Interest expense		(341	)		(472	)		(713	)		(1,006	)
RADx initiative grant income		—			200			—			1,000
Other, net		733			(883	)		572			(1,574	)
Consolidated earnings before income taxes	$	36,535		$	33,052		$	56,286		$	67,300

Consolidated Net Revenues

Individual Diagnostics or Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment net revenues were as follows:

	Three Months Ended March 31,						Six Months Ended March 31,
	2022			2021			2022			2021
Diagnostics
Customer A		6	%		10	%		9	%		11	%
Customer B		9	%		10	%		10	%		10	%
Customer C		9	%		11	%		10	%		11	%
Life Science
Customer D		13	%		9	%		13	%		14	%
Customer E		22	%		2	%		22	%		2	%